Korsuva Injection, Solution
Product Images NDC 59353-065

4 FDA label images from Vifor (international), Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Korsuva (NDC 59353-065). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Vifor (international), Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Mech 46870 C Korsuva Carton Us V20

Mech 46870 C Korsuva Carton Us V20
Korsuva (difelikefalin) Injection 65 mcg/1.3 mL (50 mcg/mL) carton packaging label for intravenous injection. The label includes product strength, dosage form, display of two single-dose vials, manufacturer Vifor (International), Inc., and additional regulatory and lot information panels. The label also features storage and handling instructions and branding from Cara Therapeutics and Vifor Pharma.*
FDA Label Image

Difelikefalin Acetate Chemical Structure (Image 01)

Difelikefalin Acetate Chemical Structure (Image 01)
Chemical structure of difelikefalin, the active ingredient in Korsuva injection. The structure shows molecular groups including amine, carboxyl, and aromatic rings, with a notation indicating association with HOAc (acetic acid).*
FDA Label Image

Figure 1: Percentage Of Subjects With Moderate-to-severe Ckd-ap Undergoing Hd With A ≥4-point Improvement From Baseline On The Wi-nrs In Trial 1 And Trial 2 (Image 02)

Figure 1: Percentage Of Subjects With Moderate-to-severe Ckd-ap Undergoing Hd With A ≥4-point Improvement From Baseline On The Wi-nrs In Trial 1 And Trial 2 (Image 02)
A chart comparing the percentage of subjects for Korsuva injection versus placebo over 12 weeks in two clinical trials. The x-axis represents weeks (0, 4, 8, 12), and the y-axis represents the percentage of subjects. Both trials show increasing percentages over time for Korsuva and placebo groups, with Korsuva consistently showing higher subject percentages than placebo.*
FDA Label Image

Korsuva (difelikefalin injection, solution)

Korsuva (difelikefalin injection, solution)
Korsuva 65 mcg/1.3 mL (50 mcg/mL) injection solution label for intravenous use. The label indicates a 1.3 mL single-dose vial, with instructions to discard unused portions. Manufactured by Cara Therapeutics, Inc., labeled for storage at 20°C to 25°C (68°F to 77°F). Product NDC 59353-065-01, Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.